

SUPPLEMENTARY MATERIAL

Supplementary Table 1. Characteristics of the included RCTs in this meta-analysis.

Study	Year	Country	Study type	Phase	Study Population	Treatment/Control,n	Regimen(dose of Nemolizumab)	Duration	Outcomes	Baseline of AD severity
Nemoto et al ^[16]	2015	Japan	RCT	I	20-49 years	18/9	0.003-3.0 mg/kg	4 months	pruritus VAS	moderate to severe
Kabashima et al ^[17]	2018	Europe, Japan and USA	RCT	II	18-65 years	208/53	0.1-2.0 mg/kg	16 months	pruritus VAS, EASI, SCORAD, IGA, BSA, DLQI	moderate to severe
Silverberg et al ^[18]	2019	multicenter	RCT	II B	18-82 years	169/57	10-90 mg	6 months	EASI, IGA, NRS	moderate to severe
Kabashima et al ^[19]	2020	multicenter	RCT	III	>13 years	143/72	60mg	4 months	EASI,VAS	moderate to severe

Supplementary Table 2. Quality assessment of included RCTs using Jadad scale.

Study	Year	Representation of randomization	Appropriateness of method for randomization	Representation of double blinding	Appropriateness of method for double blinding	Representation of withdrawals	Total score
Nemoto et al ^[16]	2015	1	1	1	1	1	5
Kabashima et al ^[17]	2018	1	1	1	1	1	5
Silverberg et al ^[18]	2019	1	1	1	1	1	5
Kabashima et al ^[19]	2020	1	1	1	1	1	5